Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
Transplantation. 2012 Oct 15;94(7):721-8. doi: 10.1097/TP.0b013e3182603297.
Calcineurin inhibitor (CNI)-based therapy is associated with adverse cardiovascular effects. We examined the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on echocardiographic parameters.
This study was conducted as a substudy of a randomized trial in stable renal transplant recipients who were on a triple CNI-based regimen with prednisone and MMF that evaluated late concentration-controlled withdrawal of CNI or MMF on renal function. A total of 108 patients (age, 52.3±11.5 years; 67% male; at a median of 2.0 years post-transplantation, (interquartile range 1.3-3.3 years); estimated glomerular filtration rate, 57±16 mL/min/1.73 m; 66% on cyclosporine and 34% on tacrolimus) entered the cardiovascular substudy examining echocardiographic parameters at baseline and 2 years after randomization. In all patients, traditional cardiovascular risk factors were treated according to predefined targets.
Late CNI withdrawal prevented progressive development of left ventricular (LV) diastolic dysfunction, as assessed by markers of LV diastolic function (mitral deceleration time and mitral annular e' velocity). Conversely, in the MMF-withdrawal group, the left atrial volume index (an indicator of chronic LV diastolic dysfunction) was significantly increased at 2 years (from 24.1±6.7 to 27.0±7.0 mL/m, P<0.05). In addition, CNI withdrawal resulted in a higher proportion of patients achieving the predefined blood pressure targets (<130/85 mm Hg: 41.5% vs. 12.7%, P=0.001) at 2 years while requiring less antihypertensive drugs. Changes in the left atrial volume index were significantly associated with treatment arm (P=0.03) and changes in systolic (P=0.005) and diastolic (P=0.005) blood pressure.
Late CNI withdrawal, from a triple-drug regimen in stable renal transplant recipients, prevented progressive deterioration of LV diastolic function and facilitated better blood pressure control.
钙调磷酸酶抑制剂(CNI)为基础的治疗与不良心血管影响有关。我们研究了 CNI 或霉酚酸酯(MMF)延迟停药对超声心动图参数的影响。
这是一项在稳定的肾移植受者中进行的随机试验的子研究,这些受者接受了三联 CNI 为基础的方案治疗,泼尼松和 MMF,并评估了 CNI 或 MMF 的晚期浓度控制停药对肾功能的影响。共有 108 例患者(年龄 52.3±11.5 岁;67%为男性;移植后中位数 2.0 年(1.3-3.3 年);估算肾小球滤过率 57±16 mL/min/1.73 m2;66%接受环孢素,34%接受他克莫司)入组了该心血管子研究,在基线和随机分组后 2 年时检查超声心动图参数。在所有患者中,根据既定目标治疗了传统心血管危险因素。
CNI 延迟停药可预防左心室(LV)舒张功能的进行性发展,LV 舒张功能的标志物(二尖瓣减速时间和二尖瓣环 e'速度)评估了这一点。相反,在 MMF 停药组中,左心房容积指数(LV 慢性舒张功能障碍的指标)在 2 年内显著增加(从 24.1±6.7 增加到 27.0±7.0 mL/m,P<0.05)。此外,CNI 停药导致在 2 年内达到既定血压目标(<130/85 mmHg:41.5% vs. 12.7%,P=0.001)的患者比例更高,同时需要更少的降压药物。左心房容积指数的变化与治疗组显著相关(P=0.03),与收缩压(P=0.005)和舒张压(P=0.005)的变化显著相关。
在稳定的肾移植受者的三联药物方案中,延迟 CNI 停药可防止 LV 舒张功能的进行性恶化,并促进更好的血压控制。